Cash Flow from Financing Activities - Cash inflows from financing activities in the first three quarters of 2024 amounted to 2,635,260,419.35, compared to 170,000,000.00 in the same period of 2023 [27] - Cash outflows from financing activities in the first three quarters of 2024 were 2,548,983,743.12, compared to 1,913,366,346.18 in the same period of 2023 [27] - Net cash flow from financing activities in the first three quarters of 2024 was 86,276,676.23, a significant improvement from -1,743,366,346.18 in the same period of 2023 [27] Net Cash and Cash Equivalents - Net increase in cash and cash equivalents in the first three quarters of 2024 was 471,988,212.11, compared to a net decrease of -1,660,285,210.64 in the same period of 2023 [27] - Ending cash and cash equivalents balance as of September 2024 was 4,216,677,812.07, up from 2,357,754,769.34 in September 2023 [27]
国药现代(600420) - 2024 Q3 - 季度财报